Keywords: AstraZeneca, R&D site overhaul, HQ move, Job cuts, Costs and savings

Major overhaul of AstraZeneca R&D sites, and HQ move, will see 1,600 job cuts

Article | 19 March 2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN), which is struggling with recent research disappointments and facing a looming $6 billion hit on ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

AstraZeneca

Go to company listing